Orthofix CEO Massimo Calafiore Sells 19,397 Shares

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Jan 13 2026

0mins

OFIX+0.79%

Should l Buy OFIX?

Source: Yahoo Finance

Executive Sell-off: Orthofix CEO Massimo Calafiore sold 19,397 shares on January 9, 2026, which may raise concerns about the company's future prospects and impact investor confidence.
Impact of Share Movement: The significant number of shares sold could be interpreted by the market as a lack of confidence in the company's current valuation or future performance, potentially exerting negative pressure on the stock price.
Market Reaction Expectations: The market may react negatively to this sell-off, prompting investors to reassess Orthofix's investment value, leading to increased stock price volatility in the short term.
Transparency and Trust: The executive's sell-off could raise questions about the company's governance transparency, affecting investor trust in the management team and potentially impacting long-term shareholder value.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy OFIX?" and start using high-conviction signals backed by rigorous historical data.

OFIX

$12.8+Infinity%1D

Analyst Views on OFIX

Wall Street analysts forecast OFIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OFIX is 21.33 USD with a low forecast of 18.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 12.700

Low

18.00

Averages

21.33

High

24.00

Current: 12.700

Low

18.00

Averages

21.33

High

24.00

TD Cowen

Hold

initiated

$14

2026-01-26

Reason

TD Cowen

Price Target

$14

AI Analysis

2026-01-26

initiated

Hold

Reason

TD Cowen initiated coverage of Orthofix with a Hold rating and $14 price target. The company is affecting enterprise-wide change while driving improving profitability and cash flow, even though its top-line acceleration is less visible today and may not be until late 2026, the analyst tells investors in a research note. TD adds that it is unequivocally positive on to-date/ongoing efforts to reshape the investment story, noting however that for the shares to "work", there needs to be evidence of accelerating sales.

Barrington

Michael Petusky

Outperform

maintain

$17 -> $18

2025-11-05

Reason

Barrington

Michael Petusky

Price Target

$17 -> $18

2025-11-05

maintain

Outperform

Reason

Barrington analyst Michael Petusky raised the firm's price target on Orthofix to $18 from $17 and keeps an Outperform rating on the shares. The company reported strong Q3 results and upped the low-end of its fiscal 2025 EBITDA outlook, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OFIX

Unlock Now

About OFIX

Orthofix Medical Inc. is a global medical technology company. The Company offers a portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH navigation system. The Company’s Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. The segment provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Orthopedics segment offers products and solutions for limb deformity correction and complex limb reconstruction with a focus on use in trauma, adult and pediatric limb reconstruction, and foot and ankle procedures.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Healthcare Stocks Surge in After-Hours Trading

Jan 28 2026NASDAQ.COM

Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.

Bone Grafts Market Report: Forecast to 2036

Jan 16 2026Globenewswire

Market Size Forecast: The report indicates significant growth in the bone grafts and substitutes market projected by 2036, with detailed intervention volumes and market value data across 39 countries aiding strategic decision-making for businesses.
Product Segmentation Analysis: It provides an in-depth analysis of various bone graft substitutes, including allograft bone chips and bone morphogenetic proteins, offering insights into market share and average selling prices to help companies optimize their product portfolios.
Competitive Dynamics Insights: Through SWOT analysis and exploration of competitive dynamics, the report reveals the market positions of key players such as Medtronic and Stryker, assisting investors in identifying potential investment opportunities.
Market Access Strategies: Additionally, the report offers detailed information on market access, including reimbursement policies and regulatory landscapes, enabling companies to formulate effective market entry strategies in a complex environment.